Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults

The Journal of Infectious Diseases
D C PowersC M Mink

Abstract

Healthy adults > or = 50 years old were immunized with either pentavalent Corynebacterium diphtheriae C7 (beta197) cross-reactive material (CRM197) protein-conjugated pneumococcal vaccine (CV) containing 10 microgram each of capsular oligosaccharides from serotypes 6B, 14, 18C, 19F, and 23F or with licensed (23-valent, 25 microgram/serotype) pneumococcal polysaccharide vaccine (PV). Adverse reactions, predominantly local in nature, occurred in 20 of 23 CV recipients versus 13 of 23 PV recipients (P<.05). Compared with mean postvaccination antibody concentrations in PV recipients, those induced by CV were not significantly different for serotypes 6B, 14, 18C, and 23F and were lower for 19F (P<.05). Six months later, reimmunization with PV of subjects who had initially received CV elicited a slight boost in antibody concentrations to levels that were not significantly higher than those achieved after the primary vaccination or than those in persons given a single dose of PV. Pneumococcal vaccines containing protein-conjugated oligosaccharides may offer no advantage over currently licensed preparations containing unconjugated polysaccharides for immunization of healthy older adults.

Citations

Oct 3, 1999·Vaccine·A A Lindberg
Jan 26, 2000·Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie·A A Lindberg
Apr 13, 1999·Infectious Disease Clinics of North America·H Ahmad, E K Chapnick
Sep 2, 1999·Infectious Disease Clinics of North America·H Peltola
Apr 17, 2001·Infectious Disease Clinics of North America·G A Poland
Jul 18, 2002·Scandinavian Journal of Immunology·T Wuorimaa, H Käyhty
Aug 7, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C G WhitneyJ C Butler
Jul 20, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel R FeikinUNKNOWN Active Bacterial Core surveillance/Emerging Infections Program Network
Jul 1, 1997·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·R Austrian
Jul 1, 1997·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·J C Butler
Aug 4, 1999·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·D L Klein
Jul 3, 1999·The Pediatric Infectious Disease Journal·J Eskola, M Anttila
Apr 5, 2000·The Pediatric Infectious Disease Journal·D S Fedson
Apr 15, 2003·Clinical Microbiology Reviews·Andrew S ArtzDan L Longo
Dec 31, 2008·Infection and Immunity·Mario A MonteiroPatricia Guerry
Apr 23, 2004·Infection and Immunity·Josée HamelBernard R Brodeur
Oct 21, 2004·Drugs & Aging·Sridhar Neralla, Keith C Meyer
Mar 4, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rajeka LazarusAndrew J Pollard
Dec 28, 2007·Vaccine·Africa González-FernándezCarmen Fernández
Jul 17, 2007·Clinics in Geriatric Medicine·Kevin High
Oct 28, 2004·Journal of the American Geriatrics Society·Kathleen R LottenbachChrisAnna M Mink
Oct 3, 2006·La Revue de médecine interne·L Temime, W Dab

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.